Geode Capital Management LLC Sells 25,287 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Geode Capital Management LLC cut its holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 8.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,887 shares of the company’s stock after selling 25,287 shares during the period. Geode Capital Management LLC’s holdings in Aerovate Therapeutics were worth $610,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Barclays PLC grew its holdings in shares of Aerovate Therapeutics by 310.8% in the third quarter. Barclays PLC now owns 18,972 shares of the company’s stock valued at $39,000 after acquiring an additional 14,354 shares in the last quarter. State Street Corp grew its holdings in shares of Aerovate Therapeutics by 7.7% in the third quarter. State Street Corp now owns 367,468 shares of the company’s stock valued at $768,000 after acquiring an additional 26,278 shares in the last quarter. FMR LLC grew its holdings in shares of Aerovate Therapeutics by 54,095.4% in the third quarter. FMR LLC now owns 82,919 shares of the company’s stock valued at $173,000 after acquiring an additional 82,766 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of Aerovate Therapeutics by 226.8% in the third quarter. GSA Capital Partners LLP now owns 413,795 shares of the company’s stock valued at $865,000 after acquiring an additional 287,163 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Aerovate Therapeutics in the second quarter valued at approximately $53,000.

Aerovate Therapeutics Stock Down 3.4 %

AVTE stock opened at $2.55 on Friday. The firm has a market cap of $73.63 million, a PE ratio of -0.85 and a beta of 1.00. The business has a 50 day moving average of $2.63 and a 200-day moving average of $2.17. Aerovate Therapeutics, Inc. has a 12-month low of $1.25 and a 12-month high of $32.42.

Aerovate Therapeutics (NASDAQ:AVTE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.03. On average, research analysts expect that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current year.

Aerovate Therapeutics Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.